T. S. Kruglova

发表

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort study

D. Chudakov, O. Tkacheva, E. Bryushkova, 2022, medRxiv.

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study

S. Lukyanov, D. Chudakov, O. Tkacheva, 2022, PLoS ONE.

Asthma among pregnant. The most actual problems of management asthma during pregnancy (a systematic review)

A. A. Pashchenko, D. Fomina, E. N. Bobrikova, 2021 .

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia

A. Chernov, A. Karaulov, Z. Mutovina, 2020, medRxiv.

[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].

E. Alexeeva, A. Chernov, Z. Mutovina, 2022, Terapevticheskii arkhiv.

[Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies].

A. Chernov, D. Fomina, A. Karaulov, 2023, Terapevticheskii arkhiv.

[Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19].

A. Chernov, Z. Mutovina, I. Samsonova, 2021, Terapevticheskii arkhiv.

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort study

D. Chudakov, I. Strazhesko, Z. Mutovina, 2022 .